Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | ARG1 | P05089 | 1/20 | 0.43 |
| ▸ | ARG2 | P78540 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | ALPI | P09923 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27962346 | 0.86 | SMN1; SMN2 (0.55) | SMN1; SMN2HIF1ASLC6A2TAAR1ARG1 | |
| SCHEMBL1274883 | 0.81 | SMN1; SMN2 (0.58) | SMN1; SMN2HIF1ASLC6A2TAAR1ARG1 | |
| SCHEMBL28136599 | 0.81 | SMN1; SMN2 (0.58) | SMN1; SMN2HIF1ASLC6A2TAAR1ARG1 | |
| SCHEMBL11265928 | 0.81 | SMN1; SMN2 (0.58) | SMN1; SMN2HIF1ASLC6A2TAAR1ARG1 | |
| SCHEMBL6981342 | 0.81 | SMN1; SMN2 (0.58) | SMN1; SMN2HIF1ASLC6A2TAAR1ARG1 | |
| SCHEMBL1274884 | 0.81 | SMN1; SMN2 (0.58) | SMN1; SMN2HIF1ASLC6A2TAAR1ARG1 | |
| Hydrochloric Acid SCHEMBL17262536 | 0.80 | SMN1; SMN2 (0.56) | SMN1; SMN2HIF1ASLC6A2TAAR1ARG1 | |
| SCHEMBL7653149 | 0.80 | SMN1; SMN2 (0.56) | SMN1; SMN2HIF1ASLC6A2TAAR1ARG1 | |
| SCHEMBL28189016 | 0.80 | SMN1; SMN2 (0.56) | SMN1; SMN2HIF1ASLC6A2TAAR1ARG1 | |
| SCHEMBL28189019 | 0.80 | SMN1; SMN2 (0.56) | SMN1; SMN2HIF1ASLC6A2TAAR1ARG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005030735-A1 | TRIAZINES DERIVATIVES AS CELL ADHESION INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2005-04-07 | — | — | WO | claimed |
| US-7638630-B2 | Very Late Antigen-4 dependent inflammatory disease; asthma, allergic rhinitis, sinusitis, conjunctivitis, food allergy, inflammatory skin disorders, autoimmune disorders, or atherosclerosis, inflammatory skin disorder; methyl 3-[2-(2,6-dichlorophenyl)-6-quinolinyl]-2-hydroxy-2-propenoate | UCB PHARMA S.A. (BE) | 2009-12-29 | — | — | US | disclosed |
| US-20080064720-A1 | 2,6-Quinolinyl And 2,6-Naphthyl Derivatives, Processes For Preparing Them And Their Uses As Vla-4 Inhibitors | UCB, S.A. (BE) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064720-A1 | 2,6-Quinolinyl And 2,6-Naphthyl Derivatives, Processes For Preparing Them And Their Uses As Vla-4 Inhibitors | VCAM1, HRH4, LTA4H | SMN1; SMN2 4507/4885HIF1A 2406/4885SLC6A2 2716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.